DO34 is primarily used in research settings as a potent and selective inhibitor of the enzyme diacylglycerol lipase alpha (DAGLα). This enzyme plays a crucial role in the biosynthesis of 2-arachidonoylglycerol (2-AG), a key endocannabinoid signaling molecule. By inhibiting DAGLα, DO34 helps scientists study the physiological and pathological roles of the endocannabinoid system, particularly in processes like neurotransmission, inflammation, and energy metabolism. Its application is valuable in understanding neurological disorders, metabolic diseases, and potential therapeutic targets.